Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead Sciences (NASDAQ: GILD) has secured an exclusive option for the MGD024 molecule, a bispecific antibody targeting CD123 and CD3, through a collaboration with MacroGenics (NASDAQ: MGNX). This molecule aims to treat blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Gilead has committed
Gilead Sciences, Inc. (Nasdaq: GILD) will release its third quarter 2022 financial results on October 27 after market close. Following the announcement, management will host a webcast at 4:30 p.m. Eastern Time to discuss results and provide a business update. The webcast will be accessible on Gilead's Investor Relations website and archived for one year. Gilead focuses on developing innovative medicines for serious diseases, including HIV, hepatitis, and cancer, operating in over 35 countries from its headquarters in Foster City, California.
Gilead Sciences, Inc. announced that the FDA accepted its supplemental Biologics License Application (sBLA) for Trodelvy to treat adult patients with unresectable HR+/HER2- metastatic breast cancer who have received prior therapies. The sBLA is based on positive data from the TROPiCS-02 study, showing significant improvements in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. The PDUFA target date is set for February 2023. While Trodelvy has not yet been approved for this indication, it has shown promise in changing treatment landscapes for breast cancer.
Kite, a Gilead Company (Nasdaq: GILD), has received FDA approval for its retroviral vector manufacturing facility in Oceanside, California. This facility is crucial for producing viral vectors, which are essential in Kite's CAR T-cell therapies aimed at treating blood cancers. Kite stands out as the only cell therapy company with both commercial and clinical trial viral vector manufacturing capabilities. The in-house production will enhance reliability and scalability, meeting increasing patient demand for these therapies.
Gilead Sciences has launched a multi-year, public-private initiative in collaboration with the Partnership for Health Advancement in Vietnam (HAIVN) to enhance hepatitis care and management in Vietnam and the Philippines. This program aims to integrate hepatitis B and C diagnosis and treatment into primary healthcare, addressing barriers to access. With significant hepatitis prevalence in both countries, the initiative aligns with WHO targets for viral hepatitis elimination by 2030, hoping to strengthen healthcare systems and broaden patient access to care.
Gilead Sciences, Inc. (GILD) has successfully completed the acquisition of MiroBio for $405 million in cash. MiroBio, a U.K.-based biotechnology firm, specializes in immune inhibitory receptor agonists. This acquisition grants Gilead access to MiroBio's proprietary discovery platform and its lead investigational antibody, MB272, which is currently in Phase 1 clinical trials. Gilead aims to enhance its portfolio in inflammatory diseases, addressing unmet medical needs.
Kite, a Gilead Company, announced a positive opinion from the European Medicines Agency for Yescarta, a CAR T-cell therapy, for adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months post-first-line chemoimmunotherapy. The ZUMA-7 study showed a four-fold improvement in event-free survival at two years (41% for Yescarta vs. 16% for standard care). The final decision from the European Commission is expected soon, potentially transforming treatment for these aggressive lymphomas.
Gilead Sciences announced a positive opinion from the European Medicines Agency (EMA) regarding its COVID-19 treatment, Veklury (remdesivir), for pediatric patients under 12 years. If approved by the European Commission, Veklury would be the only authorized antiviral treatment for this demographic, specifically for children at risk of severe COVID-19 or with pneumonia requiring oxygen. The decision is based on positive results from the ongoing CARAVAN Phase 2/3 study, which showed clinical improvement in 75-85% of pediatric participants.
Gilead Sciences announced that the World Health Organization (WHO) has updated its guidelines to include a conditional recommendation for Veklury (remdesivir) in treating both severe and non-severe COVID-19 patients at high risk of hospitalization. The decision stems from the SOLIDARITY study, demonstrating a 17% reduction in the risk of death or progression to ventilation in patients requiring supplemental oxygen. Over 11 million patients globally have received Veklury.
Gilead Sciences announces a $20 million commitment through its Creating Possible Fund to support 13 U.S. organizations focused on education and health equity. This initiative aims to build a pipeline of Black health leaders and enhance educational opportunities for underserved students. Recognizing the interconnectedness of education and health disparities, the fund will finance innovative projects that improve learning environments and social support systems. Gilead's ongoing dedication to health equity is underscored by its collaboration with local communities and organizations.